Impact of antiretroviral treatment on 13C-methionine metabolism as a marker of hepatic mitochondrial function: A longitudinal study

HIV Medicine

Volumn 12, Issue 1, 2011, Pages 40-45

  Banasch, M ^a   Frank, J ^a   Serova, K ^b   Knyhala, K ^a   Kollar, S ^a   Potthoff, A ^a   Brockmeyer, N H ^a   Goetze, O ^c  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

13C methionine breath test; Drug toxicity; HIV; Mitochondrial toxicity

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CARBON DIOXIDE; DIDANOSINE; METHIONINE C 11; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR;

ADULT; ARTICLE; BREATH ANALYSIS; CARBON DIOXIDE BREATHING; DRUG EFFECT; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER MITOCHONDRION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS REPLICATION;

ACUTE DISEASE; ADULT; ANTI-RETROVIRAL AGENTS; BREATH TESTS; CARBON ISOTOPES; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HUMANS; LIVER DISEASES; LONGITUDINAL STUDIES; MALE; METHIONINE; MIDDLE AGED; MITOCHONDRIA, LIVER; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 78650116708     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00847.x     Document Type: Article

References (19)

1. Salmon-Ceron D, Lewden C, Morlat P et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799-805.
2. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113-119.
3. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641.
4. Crum-Cianflone N, Dilay A, Collins G et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50: 464-473.
5. Guaraldi G, Squillace N, Stentarelli C et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-257.
6. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14: 193-199.
7. Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375.
8. Milazzo L, Piazza M, Sangaletti O et al. [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother 2005; 55: 84-89.
9. Banasch M, Knyhala K, Kollar S et al. Disease- and treatment-related predictors of hepatic mitochondrial dysfunction in chronic HIV infection assessed by non-invasive (13)C-methionine breath test diagnostic. Eur J Med Res 2008; 13: 401-408.
10. Banasch M, Goetze O, Hollborn I et al. 13C-methionine breath test detects distinct hepatic mitochondrial dysfunction in HIV-infected patients with normal serum lactate. J Acquir Immune Defic Syndr 2005; 40: 149-154.
11. Shedlock DJ, Hwang D, Choo AY, Chung CW, Muthumani K, Weiner DB. HIV-1 viral genes and mitochondrial apoptosis. Apoptosis 2008; 13: 1088-1099.
12. Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 2009; 64: 901-909.
13. Haugaard SB, Andersen O, Pedersen SB et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 2005; 77: 29-38.
14. Giralt M, Domingo P, Guallar JP et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 2006; 11: 729-740.
15. Gerschenson M, Kim C, Berzins B et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009; 63: 1244-1250.
16. Tebas P, Zhang J, Hafner R et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63: 998-1005.
17. Ribera E, Paradineiro JC, Curran A et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008; 9: 407-417.
18. Banasch M, Emminghaus R, Ellrichmann M, Schmidt WE, Goetze O. Longitudinal effects of hepatitis C virus treatment on hepatic mitochondrial dysfunction assessed by C-methionine breath test. Aliment Pharmacol Ther 2008; 28: 443-449.
19. Banasch M, Ellrichmann M, Schmidt WE et al. The non-invasive 13C-methionine breath test differentiates histopathological stages in patients with non-alcoholic steatohepatitis. Hepatology 2008; 48 (4 Suppl 1): 521A [479].